Chris Viehbacher, Biogen CEO (Romuald Meigneux/Sipa via AP Images)

Bio­gen cuts PhI­II Parkin­son’s pro­gram over ‘long time­line’ 

Bio­gen is call­ing it quits on a late-stage Parkin­son’s tri­al as part of an on­go­ing R&D re­or­ga­ni­za­tion.

The Cam­bridge, MA-based biotech an­nounced Mon­day morn­ing that it’s dis­con­tin­u­ing a Phase III pro­gram eval­u­at­ing BI­IB122 as a treat­ment for pa­tients with Parkin­son’s dis­ease re­lat­ed to LRRK2 mu­ta­tions with part­ner De­nali Ther­a­peu­tics. The study, dubbed LIGHT­HOUSE, kicked off in Sep­tem­ber; it was slat­ed for com­ple­tion in 2031. Bio­gen said the de­ci­sion was made in con­sid­er­a­tion of the study’s “com­plex­i­ty in­clud­ing the long time­line.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA